TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35370573

Group type: COMPARATOR
Intervention: Constant practice (CG) - practicing one pattern of step isometric contractions during unimanual index finger abduction, 90 trials in all training sessions.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Variable practice (VG) - practicing three different patterns, each practiced 30 times per session.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Constant practice (CG) - EEG activation and connectivity between cognitive, sensory, and motor cerebral cortex areas.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Variable practice (VG) - EEG activation and connectivity between cognitive, sensory, and motor cerebral cortex areas.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (CG and VG) - motor task proficiency examined before (pre-) and after practice (post- and retention tests).
Number of subjects: 50
Study: 35371427

Group type: EXPERIMENTAL
Intervention: Hetrombopag (7.5 mg once daily to a maximum of 15 mg once daily for 52 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 55
Study: 35371993

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 566
Study: 35372008

Group type: EXPERIMENTAL
Intervention: ADP-A2M10
Number of subjects: 10
Study: 35372393

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC) plus chronic transfusion regimen
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Acute transfusion approaches
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Alloimmunization
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Donor-recipient exact matching for ABO, Rhesus, and Kell antigen systems
Number of subjects: 1579
Study: 35372473

Group type: EXPERIMENTAL
Intervention: High-resolution impedance manometry (HRIM)
Number of subjects: 14
Study: 35372734

Group type: EXPERIMENTAL
Intervention: MoAb
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control
Number of subjects: 235
Study: 35373037

Group type: EXPERIMENTAL
Intervention: Vascular access support quality improvement program
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pre-program self-efficacy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Post-program self-efficacy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Program acceptability
Number of subjects: 37
Study: 35373040

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lawton Instrumental Activities of Daily Living (IADL)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Modified Mini-Mental Status Exam (M3SE)
Number of subjects: 350
Study: 35373105

Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccines (BNT162b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna])
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 35373179

Group type: EXPERIMENTAL
Intervention: Momentary self-regulation measure (four subscales: momentary perseverance, momentary sensation seeking, momentary self-judgment, momentary mindfulness)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Momentary self-regulation in smoking sample
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Momentary self-regulation in binge-eating sample
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Laddr mobile application
Number of subjects: 185
Study: 35373299

Group type: EXPERIMENTAL
Intervention: ADXS31-142 monotherapy (n = 13)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ADXS31-142 plus pembrolizumab (n = 37)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 35373878

Group type: EXPERIMENTAL
Intervention: GLP-1 RA
Number of subjects: 11430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11430
Study: 35377104

Group type: EXPERIMENTAL
Intervention: 6 months of aerobic exercise intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 144
Study: 35377133

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 12/1.5 g/24 h as a continuous infusion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regular dose of 12/1.5 g/24 h
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dosing guided by renal function and therapeutic drug monitoring
Number of subjects: 39
Study: 35377184

Group type: EXPERIMENTAL
Intervention: Plasma soluble ST2 (sST2) level
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cytokine profiles
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analyses of plasma sST2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of plasma sST2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Diagnostic validation of plasma sST2
Number of subjects: 76
Study: 35377567

Group type: EXPERIMENTAL
Intervention: Resting State MRI Amplitude of Low Frequency Fluctuations
Number of subjects: 0
Study: 35377699

Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale 3.0 (SIS 3.0)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PROMIS Depression Short Form v8b
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Caregiver Strain Index
Number of subjects: 29
Study: 35378489

Group type: EXPERIMENTAL
Intervention: Targeted RNA-based Next-Generation Sequencing (tRNA-seq) using Archer FusionPlex
Number of subjects: 126

Group type: COMPARATOR
Intervention: Targeted DNA-based Next-Generation Sequencing (tDNA-seq)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: tRNA-seq
Number of subjects: 126
Study: 35378590

Group type: EXPERIMENTAL
Intervention: Minimally invasive discectomy
Number of subjects: 222
Study: 35378634

Group type: EXPERIMENTAL
Intervention: MammaPrint Low Risk, Luminal A-type and HER2-type tumors
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: MammaPrint High Risk, Luminal B-type and Basal-type tumors
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Low-Risk tumors
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: High-Risk tumors
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: BluePrint subtypes
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 954
Study: 35378640

Group type: EXPERIMENTAL
Intervention: Adjuvant multisession radiosurgery (mRS) - 22 patients received 28 Gy in 4 fractions, 2 patients received 24 Gy in 4 fractions.
Number of subjects: 24
Study: 35378750

Group type: EXPERIMENTAL
Intervention: Parent Intervention (PI)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Summer Camp (SCV)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of Summer Camp and Parent Intervention (SCV + PI)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Summer Programming Attendance
Number of subjects: 89
Study: 35378952

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg BID on the first day, then 400 mg OD for a total of seven days
Number of subjects: 1372
Study: 35379237

Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg combined with low-dose dexamethasone (20 mg) administered orally on day 1 and day 3 of each week in 4-week cycles
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Selinexor 80 mg combined with low-dose dexamethasone (20 mg)
Number of subjects: 82
Study: 35379312

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 278
Study: 35379337

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CalRes) microbiota
Number of subjects: 0

Group type: COMPARATOR
Intervention: AdLib microbiota
Number of subjects: 0
Study: 35379597

Group type: EXPERIMENTAL
Intervention: GVFQ-40 (Glaucoma Visual Functioning Questionnaire)
Number of subjects: 354

Group type: COMPARATOR
Intervention: NEI VFQ-25 (National Eye Institute Visual Functioning Questionnaire-25)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: GVFQ-40 (test-retest reliability)
Number of subjects: 354
Study: 35379611

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibody in arm A (obvious response to TKIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) in arm B (general response to TKIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) in arm C (poor response to TKIs)
Number of subjects: 0
Study: 35379610

Group type: EXPERIMENTAL
Intervention: MAVIPAN longitudinal prospective cohort study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative data collection through online questionnaires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through individual and group interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-method analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support healthcare and social services system response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guide public health authorities' decision making
Number of subjects: 0
Study: 35379612

Group type: EXPERIMENTAL
Intervention: Platelet transmission electron microscopy
Number of subjects: 50
Study: 35379615

Group type: EXPERIMENTAL
Intervention: ABCD criteria for visual inspection with acetic acid
Number of subjects: 1980
Study: 35379630

Group type: EXPERIMENTAL
Intervention: Weekly text messages with three short questions assessing mood, worry, and pain (n=1851 subgroup)
Number of subjects: 5000
Study: 35379635

Group type: EXPERIMENTAL
Intervention: Signal functions for emergency readiness
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CEmOC facilities
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clinical cascade model
Number of subjects: 23
Study: 35379641

Group type: EXPERIMENTAL
Intervention: Opt-out interferon gamma release assay blood test for LTBI screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative analysis through semistructured interviews or focus groups
Number of subjects: 0
Study: 35379737

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (3 cycles of neoadjuvant therapy including three doses for 21 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (neoadjuvant therapy followed by surgery)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (adjuvant therapy after surgery)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (during preoperative phase)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (with ctDNA analysis)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (comparison of mutations)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: camrelizumab plus apatinib (ctDNA status after adjuvant therapy)
Number of subjects: 18
Study: 35379815

Group type: EXPERIMENTAL
Intervention: BBIBP-CorV vaccine
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1006
Study: 35379845

Group type: EXPERIMENTAL
Intervention: Antifolate therapy
Number of subjects: 0
Study: 35379863

Group type: EXPERIMENTAL
Intervention: Endotoxin (LPS) challenge
Number of subjects: 10
Study: 35379963

Group type: EXPERIMENTAL
Intervention: EasyFuse (machine learning computational pipeline for detecting cancer-specific gene fusions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing immunogenicity with autologous blood lymphocytes
Number of subjects: 0
Study: 35379979

Group type: EXPERIMENTAL
Intervention: Intravitreal sepofarsen 160 µg/80 µg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravitreal sepofarsen 320 µg/160 µg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravitreal sepofarsen (both dosages)
Number of subjects: 11
Study: 35380495

Group type: EXPERIMENTAL
Intervention: Transfontanellar contrast-enhanced ultrasound (T-CEUS)
Number of subjects: 0
Study: 35380627

Group type: EXPERIMENTAL
Intervention: Breakfast timing (first eating occasion of the day between 07:00-09:00)
Number of subjects: 3747

Group type: COMPARATOR
Intervention: Breakfast timing (first eating occasion after 09:00)
Number of subjects: 3747

Group type: COMPARATOR
Intervention: Eating breakfast daily
Number of subjects: 3747
Study: 35380673

Group type: EXPERIMENTAL
Intervention: Crohn's disease patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients with central sensitization (CS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients with CS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall IBD patients
Number of subjects: 200
Study: 35380726

Group type: EXPERIMENTAL
Intervention: Rh-endostatin plus irinotecan/cisplatin
Number of subjects: 50
Study: 35381327

Group type: EXPERIMENTAL
Intervention: Transcarotid artery revascularization (TCAR) using the ENROUTE Transcarotid Stent System
Number of subjects: 155
Study: 35381950

Group type: EXPERIMENTAL
Intervention: Free triiodothyronine (FT3) concentration
Number of subjects: 106

Group type: COMPARATOR
Intervention: Thyroid-stimulating hormone (TSH)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Free thyroxine
Number of subjects: 106
Study: 35382119

Group type: EXPERIMENTAL
Intervention: SPIN-HAND program (online hand exercise intervention) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 35382436

Group type: EXPERIMENTAL
Intervention: sMRI-guided radiation therapy (RT) dose escalation to 75 Gy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sMRI-guided RT dose escalation to 75 Gy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard RT to 60 Gy
Number of subjects: 30
Study: 35382761

Group type: EXPERIMENTAL
Intervention: Simplified echocardiographic method using e' and E/e'
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 96
Study: 35382819

Group type: EXPERIMENTAL
Intervention: Apatinib combined with oxaliplatin and capecitabine
Number of subjects: 35
Study: 35382822

Group type: EXPERIMENTAL
Intervention: INDI collaborative care program
Number of subjects: 23
Study: 35382877

Group type: EXPERIMENTAL
Intervention: MSI prevention program implementation
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: MSI cases with no consequences
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: MSI cases with mild consequences
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: MSI cases with severe consequences
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: Textile elements retention
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: Improper reporting of cases
Number of subjects: 559910

Group type: EXPERIMENTAL
Intervention: Risk factors for MSIs
Number of subjects: 559910
Study: 35382891

Group type: EXPERIMENTAL
Intervention: Building Health Families (BHF) intervention with an action Learning Collaborative (LC) strategy including network weaving, consultee-centered training, goal-setting and feedback, and sustainability action planning over a 12-month period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies associated with BHF program implementation.
Number of subjects: 0
Study: 35382916

Group type: EXPERIMENTAL
Intervention: Influenza vaccination coverage (IVC) of healthcare workers (HCWs)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: IVC ≥40% of HCWs
Number of subjects: 165
Study: 35383044

Group type: EXPERIMENTAL
Intervention: Staff-Assisted Peritoneal Dialysis Program
Number of subjects: 0
Study: 35383069

Group type: EXPERIMENTAL
Intervention: Computerised-decision support system (CDSS) for antibiotic stewardship (APSS) and electronic surveillance software (ESS) for infection surveillance (ZINC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDSS/ESS
Number of subjects: 0
Study: 35383076

Group type: EXPERIMENTAL
Intervention: Whole genome sequencing results
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Non-invasive quantitative MRI scan
Number of subjects: 200
Study: 35383088

Group type: EXPERIMENTAL
Intervention: Mobile health intervention with 2 weekly text messages for 3 months after CR completion.
Number of subjects: 40
Study: 35383100

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide (OW semaglutide)
Number of subjects: 1212
Study: 35383117

Group type: EXPERIMENTAL
Intervention: Abatacept (60 mg/kg in three doses of 20 mg/kg each within the first 10 days, followed by two doses) combined with ruxolitinib and methylprednisolone
Number of subjects: 1

Group type: COMPARATOR
Intervention: Corticosteroids and mycophenolate-mofetil (initial treatment before abatacept)
Number of subjects: 1
Study: 35383335

Group type: EXPERIMENTAL
Intervention: Common genetic variants (GPR139, DACH1, APOE)
Number of subjects: 15640

Group type: EXPERIMENTAL
Intervention: Longitudinal magnetic resonance imaging data
Number of subjects: 15640

Group type: EXPERIMENTAL
Intervention: Genetic overlap findings
Number of subjects: 15640

Group type: EXPERIMENTAL
Intervention: Gene set findings
Number of subjects: 15640
Study: 35383374

Group type: EXPERIMENTAL
Intervention: Cefotaxime 150 mg/kg/day (interval 6-8 h)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cefotaxime 200 mg/kg/day (interval 6 h)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cefotaxime with increased frequency (interval 4 h)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Loading dose followed by continuous infusion regimens
Number of subjects: 52
Study: 35383466

Group type: EXPERIMENTAL
Intervention: Combined imaging (echocardiogram and magnetic resonance imaging) and genetic (whole exome sequencing) evaluation, together with physical examination and psychological assessment.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined imaging and genetic evaluation.
Number of subjects: 70
Study: 35383569

Group type: EXPERIMENTAL
Intervention: STOP-BANG screening tool
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale
Number of subjects: 120

Group type: COMPARATOR
Intervention: Polysomnography (reference standard)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Secondary analysis (1B-criteria)
Number of subjects: 120
Study: 35383660

Group type: EXPERIMENTAL
Intervention: Combined deep brain stimulation (DBS) using bilateral STN and GP leads
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combined DBS with multiple electrodes activated
Number of subjects: 3

Group type: COMPARATOR
Intervention: STN DBS alone
Number of subjects: 3

Group type: COMPARATOR
Intervention: GP DBS alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combined DBS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 3
Study: 35383885

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 320 mg once daily (QD)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily (BID)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Zanubrutinib (both dosages)
Number of subjects: 44
Study: 35383887

Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 8474
Study: 35383907

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35383979

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) catheter ablation guided by DirectSense™ algorithm
Number of subjects: 48
Study: 35384351

Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 36
Study: 35384504

Group type: EXPERIMENTAL
Intervention: 23-h surgery
Number of subjects: 993
Study: 35384522

Group type: EXPERIMENTAL
Intervention: Verubecestat (DBS sampling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verubecestat (Plasma sampling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verubecestat (Population PK models)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DBS data from APECS study
Number of subjects: 0
Study: 35384529

Group type: EXPERIMENTAL
Intervention: Verubecestat in dried blood spot (DBS) samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New DBS handling procedures with increased desiccant
Number of subjects: 0
Study: 35384556

Group type: EXPERIMENTAL
Intervention: Community-based cervical cancer screening education for men
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Engagement of men in health system barriers discussions
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Support services for women
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Decentralization of services for men
Number of subjects: 23
Study: 35384873

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) alone
Number of subjects: 1954
Study: 35385120

Group type: EXPERIMENTAL
Intervention: Prechtl General Movement Assessment (GMA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Motor Optimality Score
Number of subjects: 12
Study: 35385418

Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Difficult laryngoscopy (Cormack and Lehane's grade III or IV)
Number of subjects: 80
Study: 35385466

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSS) and soft tissue therapy (STT) for 5 consecutive days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Routine NICU care
Number of subjects: 104
Study: 35385480

Group type: EXPERIMENTAL
Intervention: Rivaroxaban initiated < 72 hours after reperfusion therapy
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Rivaroxaban initiated ≥ 72 hours after reperfusion therapy
Number of subjects: 1333
Study: 35385726

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined inhibition of HER2/3 and AR or mTORC1
Number of subjects: 94
Study: 35385748

Group type: EXPERIMENTAL
Intervention: BRAF/MEK inhibitor combination therapy
Number of subjects: 772
Study: 35385922

Group type: EXPERIMENTAL
Intervention: Nilotinib (initial dose 400 mg twice daily, later reduced to 300 mg twice daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 73
Study: 35385975

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 142815

Group type: COMPARATOR
Intervention: Tinzaparin
Number of subjects: 142815

Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 142815

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 142815
Study: 35385993

Group type: EXPERIMENTAL
Intervention: Tepotinib (oral MET kinase inhibitor)
Number of subjects: 0
Study: 35386404

Group type: EXPERIMENTAL
Intervention: Robotically-assisted cochlear implantation surgery (RACIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Image-guided surgery
Number of subjects: 0